Beam Therapeutics CMO Sells 6,700 Shares for Taxes

Beam Therapeutics Inc. Chief Medical Officer Amy Simon reported an open-market sale of 6,700 shares of common stock at $24.58 per share.

Rhea-AI Filing Summary

Beam Therapeutics Inc. Chief Medical Officer Amy Simon reported an open-market sale of 6,700 shares of common stock at $24.58 per share. According to the filing, these shares were automatically sold to cover tax withholding obligations tied to vesting of restricted stock units under Beam’s 2019 Equity Incentive Plan and were executed under a pre-arranged Rule 10b5-1 trading plan. After this transaction, Simon directly holds 102,735 Beam shares, and the total includes shares acquired through the company’s Employee Stock Purchase Plan.

Insider Trade Summary 10b5-1

Net Seller: 6,700 shares

Net Sell 1 txn

Insider Simon Amy

Role Chief Medical Officer

Sold 6,700 shs ($165K)

Type	Security	Shares	Price	Value
Sale	Common Stock	6,700	$24.58	$165K

Holdings After Transaction: Common Stock — 102,735 shares (Direct)

Footnotes (2)

1. F1. These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan on each of March 31, 2022, March 31, 2023, March 31, 2024 and March 31, 2025. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2023.
2. F2. Includes 183 and 138 shares acquired by the Reporting Person under the BEAM Amended and Restated 2019 Employee Stock Purchase Plan on September 30, 2025 and March 31, 2026, respectively.

Key Figures

Shares sold: 6,700 shares Sale price: $24.58 per share Shares held after: 102,735 shares +2 more

5 metrics

Shares sold 6,700 shares Common stock sold on April 1, 2026

Sale price $24.58 per share Price for the 6,700 sold shares

Shares held after 102,735 shares Direct common stock holdings following the transaction

ESPP shares acquired Sept. 30, 2025 183 shares Acquired under Amended and Restated 2019 Employee Stock Purchase Plan

ESPP shares acquired Mar. 31, 2026 138 shares Acquired under Amended and Restated 2019 Employee Stock Purchase Plan

Key Terms

restricted stock units, Rule 10b5-1 trading plan, 2019 Equity Incentive Plan, Employee Stock Purchase Plan

4 terms

restricted stock units financial

"to cover tax withholding obligations upon the vesting of certain restricted stock units granted"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Rule 10b5-1 trading plan regulatory

"The sales were effected pursuant to a Rule 10b5-1 trading plan adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

2019 Equity Incentive Plan financial

"granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan"

Employee Stock Purchase Plan financial

"acquired by the Reporting Person under the BEAM Amended and Restated 2019 Employee Stock Purchase Plan"

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Beam Therapeutics (BEAM) disclose for Amy Simon?

Beam Therapeutics reported that Chief Medical Officer Amy Simon sold 6,700 shares of common stock at $24.58 per share. The filing states the shares were sold automatically to cover tax withholding obligations related to vesting restricted stock units under a company equity plan.

Why were Amy Simon’s Beam Therapeutics shares sold in this Form 4 filing?

The filing explains the 6,700 shares were automatically sold to cover tax withholding obligations from vesting restricted stock units. These awards were granted under Beam’s 2019 Equity Incentive Plan and vested on several March 31 dates, triggering the tax-related share sale.

Was Amy Simon’s Beam Therapeutics share sale made under a trading plan?

Yes. The filing notes the tax-related share sales were executed under a Rule 10b5-1 trading plan adopted on May 19, 2023. Such plans pre-schedule trades, which can make transaction timing more routine and less indicative of discretionary market views.

How many Beam Therapeutics shares does Amy Simon hold after this Form 4?

After the reported transaction, Amy Simon directly holds 102,735 shares of Beam Therapeutics common stock. This figure includes shares obtained through equity awards and employee stock purchase plan participation, as described in the filing’s explanatory footnotes.

What equity plans are mentioned in Beam Therapeutics’ Form 4 for Amy Simon?

The Form 4 references the Beam Therapeutics 2019 Equity Incentive Plan and the Amended and Restated 2019 Employee Stock Purchase Plan. Restricted stock units vested under the incentive plan, and additional shares were acquired through the purchase plan on specified September 30 and March 31 dates.

Does Amy Simon’s Beam Therapeutics share sale reflect an open-market decision?

The transaction is coded as an open-market sale, but the footnote clarifies it was an automatic sale to satisfy tax withholding on vesting restricted stock units. It was carried out under a pre-arranged Rule 10b5-1 trading plan, signaling a tax and plan-driven event.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/06/2026 - 05:44 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Simon Amy

(Last) (First) (Middle)

C/O BEAM THERAPEUTICS INC.,

238 MAIN STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Beam Therapeutics Inc. [ BEAM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/01/2026		S(1)		6,700	D	$24.58	102,735(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan on each of March 31, 2022, March 31, 2023, March 31, 2024 and March 31, 2025. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2023.

2. Includes 183 and 138 shares acquired by the Reporting Person under the BEAM Amended and Restated 2019 Employee Stock Purchase Plan on September 30, 2025 and March 31, 2026, respectively.

	By: /s/ Christine Bellon, Attorney-in-fact	04/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)